Skip to content
OpenCapital
Get started

Recursion Pharmaceuticals, Inc. RXRX Purchase of an equity investment

Other financials

Income statement

See full
Revenue$6.5M-56.1%
Gross profit-$6.0M+15.0%
Operating income-$128.5M+32.8%
Net income-$117.5M+42.0%
EPS (diluted)-$0.22+56.0%

Balance sheet

See full
Cash & equivalents$665.2M+30.6%
Total debt$88.6M-24.6%
Total equity$1.0B+9.7%
Total assets$1.3B+2.6%

Cash flow

See full
Operating cash flow-$81.1M+38.5%
CapEx$258.0K-85.9%
Free cash flow-$81.4M+39.2%

Valuation

See full
Market cap$1.71B-23.7%
Enterprise value$1.14B-39.8%
P/S25.8×-11.8×

Profitability

See full
Gross margin7.2%—
Operating margin-881.3%-66.8pp
Net margin-842.9%-92.4pp
FCF margin-490.7%-102pp

Returns & leverage

See full
Return on equity-57.2%-14.4pp
Debt / equity0.1×0.0×
Current ratio5.5×+1.4×

Where this comes from

Reported directly by Recursion Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept rxrx:PurchaseOfAnEquityInvestmentNonCash.

The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Recursion Pharmaceuticals, Inc.'s purchase of an equity investment.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Recursion Pharmaceuticals, Inc.'s purchase of an equity investment?
Recursion Pharmaceuticals, Inc. (RXRX) reported purchase of an equity investment of $0 in Q1 2026.
How has Recursion Pharmaceuticals, Inc.'s purchase of an equity investment changed year-over-year?
Recursion Pharmaceuticals, Inc.'s purchase of an equity investment decreased by 100.0% year-over-year, from $4.44M to $0.